- Home
- MFIN vs VRXA Comparison
MFIN vs VRXA Comparison
Compare MFIN & VRXA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MFIN | VRXA |
|---|---|---|
| Founded | 1995 | N/A |
| Country | United States | Switzerland |
| Employees | 179 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 229.0M | 263.0M |
| IPO Year | N/A | 2025 |
Fundamental Metrics
Financial Performance| Metric | MFIN | VRXA |
|---|---|---|
| Price | $11.92 | $1.38 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $12.00 | N/A |
| AVG Volume (30 Days) | 75.4K | ★ 141.4K |
| Earning Date | 04-29-2026 | N/A |
| Dividend Yield | ★ 5.18% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.02 | N/A |
| P/E Ratio | $6.21 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.85 | $1.37 |
| 52 Week High | $12.07 | $4.50 |
Technical Indicators
Market Signals| Indicator | MFIN | VRXA |
|---|---|---|
| Relative Strength Index (RSI) | 69.51 | 26.44 |
| Support Level | $9.19 | N/A |
| Resistance Level | N/A | $2.29 |
| Average True Range (ATR) | 0.29 | 0.14 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 86.35 | 4.54 |
Price Performance
Historical ComparisonAbout MFIN Medallion Financial Corp.
Medallion Financial Corp is a finance company that originates and services loans in various industries. The four operating segments are, (1) recreation, (2) home improvement, (3) commercial and (4) taxi medallion The company generates maximum revenue from the Recreation segment. The company's geographic Concentrations are in united states diversified in California, Wisconsin, New York, Texas and others.
About VRXA Veraxa Biotech AG Ordinary Shares
Veraxa Biotech Holding AG focus on antibody therapies in medicine. The Company is an oncology-focused biotechnology Company with a clinical program in acute myeloid leukemia and two proprietary platform technologies that enable the development of new generations of antibody drug conjugates (ADC's) and T cell engagers. The Company operates in one reportable segment, focused on the research and development of products for the aging population.